Quipt Home Medical stock hits 52-week low at $2.3 amid challenges

Published 20/03/2025, 21:02
Quipt Home Medical stock hits 52-week low at $2.3 amid challenges

Quipt Home Medical (TASE:BLWV) Corp. (QIPT) stock has reached a 52-week low, touching down at $2.3, as the company grapples with market headwinds. With a market capitalization of approximately $100 million and annual revenue of $245 million, InvestingPro analysis suggests the stock is currently trading below its Fair Value. Over the past year, the home medical equipment provider has seen its stock price significantly retreat, with a 1-year change showing a decline of 46.53%. This downturn reflects investor concerns over the company’s performance and broader market trends affecting the healthcare sector. Despite current challenges, analysts maintain a Strong Buy consensus with price targets ranging from $4.00 to $8.25, suggesting significant upside potential. Quipt’s management is likely to face increased pressure to implement strategic measures to stabilize the stock price and reassure stakeholders of the company’s growth potential moving forward. Additional insights and detailed analysis are available in the comprehensive Pro Research Report on InvestingPro.

In other recent news, Quipt Home Medical Corp reported its first-quarter earnings for 2025, revealing mixed results. The company posted an earnings per share (EPS) of -$0.03, surpassing the forecasted -$0.08, while revenue slightly missed expectations, coming in at $61.4 million against a forecast of $61.7 million. Despite the revenue miss, Quipt Home Medical continues to aim for 8-10% organic growth for 2025. The company is also focusing on improving its EBITDA margins, with a long-term target of reaching a 25% margin. Analysts from Canaccord Genuity highlighted the $2.5 million headwind expected in 2025 due to a terminated disposable supply contract. Additionally, Quipt Home Medical is managing challenges related to its Humana (NYSE:HUM) contract, which will mostly affect the first two quarters. The company remains optimistic about potential Medicare reimbursement reinstatement, which could positively impact future operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.